Acadian Asset Management
FENC icon

Acadian Asset Management’s Fennec Pharmaceuticals FENC Stock Holding History

Acadian Asset Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,059
Closed -$207K – 2086
2025
Q4 		$207K Buy
27,059
+16,351
+153% +$134K ﹤0.01% 1517
2025
Q3 		$100K Buy
+10,708
New +$92.7K ﹤0.01% 1524
2024
Q3 		– Sell
-8,086
Closed -$49K – 2163
2024
Q2 		$49K Buy
+8,086
New +$67.2K ﹤0.01% 1607

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Acadian Asset Management's FENC Position: Q1 2026 in Review

Acadian Asset Management sold out of Fennec Pharmaceuticals (FENC) in Q1 2026, closing a stake of 27,059 shares — an estimated $207K sold.

Acadian Asset Management first reported a position in FENC in Q2 2024 and held it in 3 quarters. The position peaked at $207K in Q4 2025. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Acadian Asset Management reported no remaining Fennec Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 27,059 Fennec Pharmaceuticals shares in Q1 2026, an estimated $207K.
  • Acadian Asset Management first reported a position in Fennec Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Acadian Asset Management's Fennec Pharmaceuticals position peaked at $207K in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.